Key Takeaways
- New York Fed President John Williams maintains that current interest rate policy is "well positioned" to achieve the 2% inflation target, though he warned the Fed will act if progress on price stability stalls.
- Tesla (TSLA) saw new car registrations in Spain plummet 81.3% year-over-year in July, with only 131 units registered, according to industry group ANFAC.
- Loews Corporation (L) reported a strong second quarter with EPS of $2.16, significantly outperforming the $1.87 recorded in the same period last year.
- AstraZeneca (AZN) officially launched its cancer drug Imjudo in China, targeting long-term survival for patients with advanced liver cancer.
Federal Reserve Maintains "Steady-Hawk" Stance
New York Federal Reserve President John Williams affirmed his confidence on Monday that the central bank's current monetary policy is sufficient to guide inflation back to its 2% goal. Despite acknowledging that inflation remains "unquestionably too high" at approximately 4%, Williams expressed optimism that price pressures will gradually ease as the impacts of tariffs and energy spikes from the Middle East war begin to cool.
Williams noted that the Fed is not "obliged to ratify" market pricing but views it as a valuable source of information. He emphasized that the Federal Open Market Committee (FOMC) remains committed to price stability and will not hesitate to adjust rates if the economy deviates from its disinflationary trajectory. Additionally, he downplayed financial stability risks from the AI sector, despite recent market volatility.
Tesla Faces Sharp Decline in Spanish Market
Data from the ANFAC industry group revealed a staggering 81.3% drop in Tesla (TSLA) registrations in Spain for July 2026. The company registered just 131 cars, a sharp reversal from the growth trends seen earlier in the year. This decline comes amid a mixed European landscape where Tesla has seen surges in markets like France (+86%) but near-total collapses in others like Norway (-97%).
Industry analysts suggest the volatility may be tied to the exhaustion of local subsidies and increased competition from Chinese EV manufacturers. While Tesla's second-quarter global deliveries previously beat estimates, the July data highlights significant regional headwinds in Southern Europe.
Loews and AstraZeneca Post Key Developments
Loews Corporation (L) delivered robust second-quarter 2026 results, reporting net income of $444 million. Revenue rose 3.9% year-over-year to $4.73 billion, driven by strong performance across its diversified portfolio, including CNA Financial (CNA) and its hospitality division. The company's adjusted book value per share also saw a healthy increase to $99.27, up from $91.66 a year ago.
In the pharmaceutical sector, AstraZeneca (AZN) expanded its oncology footprint by launching Imjudo (tremelimumab) in China. The drug is indicated for use in combination with Imfinzi for the treatment of adult patients with unresectable hepatocellular carcinoma (HCC). This launch is a critical step for the company in the Chinese market, where over 180,000 patients are diagnosed with embolization-eligible liver cancer annually.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.